微流体合成的充满阿齐思罗米的奇托桑纳米颗粒:对Toxoplasma gondii和小鼠模型中的组织囊的影响
Mohammad Mahdi Heidari1, Asghar Fazaeli1, Samad Nadri2
1Department of Parasitology and Mycology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Iranian journal of parasitology
|April 10, 2025
概括
装有阿齐思罗米的奇托桑纳米颗粒并没有显著减少小鼠Toxoplasma gondii组织囊. 这项研究探讨了纳米粒子合成和药物输送的潜在的抗寄生虫应用.
科学领域:
- 纳米技术纳米技术
- 寄生虫学的寄生虫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 毒素菌感染是一个严重的健康问题.
- 开发有效的毒素菌治疗方法仍然是优先事项.
- 研究新的药物输送系统对于改善治疗结果至关重要.
研究的目的:
- 在小鼠模型中评估含有阿齐思罗米的奇托桑纳米颗粒在减少Toxoplasma gondii脑组织囊方面的有效性.
- 为了表征合成的奇托桑纳米粒子和含有阿齐思罗素的纳米粒子.
- 评估纳米颗粒的药物载荷能力,释放特征和稳定性.
主要方法:
- 用微流体系统合成了基托桑纳米粒子和含有亚齐胺的纳米粒子.
- 纳米粒子的特点是动态光散射 (DLS) 和传输电子显微镜 (TEM).
- 感染T. gondii的BALB/c小鼠每天接受10天的PBS,阿兹罗迈辛,基托桑纳米颗粒或含有阿兹罗迈辛的基托桑纳米颗粒治疗,随后对大脑中的囊负担进行评估.
主要成果:
- 合成的纳米粒子表现出特定的颗粒大小和分散指数,而含有亚齐胺的纳米粒子显示出更好的分散.
- 药物载荷为1.8%,超过90%的药物在48小时内释放,并且在28天内具有良好的纳米粒子稳定性.
- 不同治疗组之间没有观察到Toxoplasma组织囊数量的显著差异.
结论:
- 微流体合成提供了具有高药载荷能力的均和稳定的奇托桑纳米颗粒.
- 在这种小鼠模型中,含有阿齐思罗米的奇托桑纳米颗粒并没有显著减少T. gondii脑囊负担.
- 可能需要进一步的研究来优化纳米粒子配方或探索毒素菌的替代治疗策略.
相关概念视频
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
647
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
647
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
158
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
158